Novo Nordisk A/S

TrumpRx Expands: Platform Adds Generic Drugs and New Pharmacy Tools The Trump administration is scaling its direct-to-consumer drug pricing platform, TrumpRx.gov, with a significant expansion of its offerings. On Monday, …

Wegovy HD Approved: A Novel Era in Weight Loss Treatment The U.S. Food and Drug Administration (FDA) has approved Wegovy HD (semaglutide) injection 7.2 mg, a higher dose of the …

GLP-1 Drugs Reshape Restaurant and Food Industries The rising adoption of GLP-1 receptor agonist medications, initially designed for managing type 2 diabetes, is significantly impacting the restaurant and food industries, …

Lilly’s Retatrutide Shows Promise in Type 2 Diabetes Trial, Delivering Significant Weight Loss Eli Lilly and Company announced positive topline results from the TRANSCEND-T2D-1 Phase 3 clinical trial evaluating retatrutide, …

Declining Birth Rates in Ukraine and Russia: A Looming Demographic Crisis Four years of war between Russia and Ukraine are beginning to capture their toll on the countries’ demographics, as …

Eli Lilly Launches Zepbound KwikPen for More Convenient Weight Management Eli Lilly and Company announced on Monday the availability of a new delivery option for its blockbuster obesity drug, Zepbound …

Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker’s new Wegovy obesity pill and injections in …

Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market. Novo Nordisk, maker of Wegovy, and the U.S. Food …

Key Takeaways from Jim Cramer’s Healthcare Sector Analysis: Here’s a breakdown of the main points from Jim Cramer’s analysis, geared towards potential investment opportunities: Overall Sentiment: Cramer is bullish on …

Novo Nordisk‘s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker fights to regain investor confidence in its …